

## Rearranged Calamenene and Eudesmane Sesquiterpenoids from two Chinese Liverworts


by Bin Ma, Zhi-Qiang Lu, Huai-Fang Guo, and Hong-Xiang Lou\*

School of Pharmaceutical Sciences, Shandong University, Jinan 250012, P. R. China  
(phone: +86-531-88382019; fax: +86-531-88382019; e-mail: louhongxiang@sdu.edu.cn)

Four novel rearranged calamenene sesquiterpenoids, **1–4**, and two eudesmane sesquiterpenoids, **5** and **6**, were isolated from the Chinese liverworts *Chiloscyphus polyanthus* (L.) and *Bazzania japonica* S. (LAC.) LINDB. Their structures and relative configurations were determined by chemical derivatization and in-depth spectroscopic methods, especially 1D- and 2D-NMR as well as HR-MS analyses.

**Introduction.** – Liverworts are rich sources of terpenoids often containing pharmacologically active compounds [1][2]. Thus, many novel sesquiterpenoids have been reported from, e.g., *C. polyanthus* (L.) [3][4] and *B. japonica* S. (LAC.) LINDB. [5][6], two widespread liverworts in China.

During our studies on antifungal components from Chinese liverworts [3][7][8], we isolated six new natural products. These include four sesquiterpenoids with an unprecedented rearranged calamenene skeleton, chiloscyphenol A (**1**) and B (**2**), and chiloscyphone A (**3**) from *C. polyanthus*, and bazzaniol A (**4**) from *B. japonica*, as well as two novel eudesmane sesquiterpenes, compounds **5** and **6**, from *C. polyanthus*.



**Results and Discussion.** – The molecular formula of the optically active compound **1**,  $[\alpha]_D^{22} = +38.2$  ( $c = 2.64$ , MeOH), was found to be C<sub>15</sub>H<sub>22</sub>O, as determined by HR-EI-MS ( $m/z$  218.1659). Four degrees of unsaturation, three Me groups at tertiary C-atoms

and one at an aromatic ring, two CH<sub>2</sub> and three CH groups, as well as two aromatic H-atoms suggested that **1** was a calamenene-type sesquiterpenoid. However, its <sup>13</sup>C-NMR data (Table 1) were somewhat different from those of *trans*- or *cis*-7-hydroxycalamene [9], which suggested an altered substitution pattern on the aromatic ring.

Table 1. <sup>1</sup>H- and <sup>13</sup>C-NMR Data for **1**–**4**. At 600 (<sup>1</sup>H) and 150 MHz (<sup>13</sup>C), resp., in CDCl<sub>3</sub>; δ in ppm, *J* in Hz. Arbitrary atom numbering.

Position	<b>1</b>		<b>1a</b>		<b>2</b>		<b>3</b>		<b>4</b>	
	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C
1	2.73 ( <i>dd</i> , <i>J</i> =6.6, 14.3)	32.2	2.76–2.80 ( <i>m</i> )	32.3	2.72 ( <i>dd</i> , <i>J</i> =6.7, 13.3)	31.5	2.84 ( <i>d</i> , <i>J</i> =6.0)	30.2	2.73 ( <i>dd</i> , <i>J</i> =7.0, 12.8)	32.3
2	1.32–1.39 ( <i>m</i> )	31.1	1.37–1.42 ( <i>m</i> )	30.6	1.17–1.25 ( <i>m</i> )	30.0	1.51–1.55 ( <i>m</i> )	32.1	1.31–1.37 ( <i>m</i> )	31.1
	1.94–1.99 ( <i>m</i> )		1.97–2.02 ( <i>m</i> )		1.94–1.98 ( <i>m</i> )		1.85–1.87 ( <i>m</i> )		1.92–1.99 ( <i>m</i> )	
3	1.55–1.62 ( <i>m</i> )	21.5	1.57–1.62 ( <i>m</i> )	20.9	1.60–1.67 ( <i>m</i> )	21.2	2.43–2.49 ( <i>m</i> )	37.5	1.58–1.65 ( <i>m</i> )	21.7
	1.83–1.88 ( <i>m</i> )		1.86–1.90 ( <i>m</i> )		1.68–1.73 ( <i>m</i> )		2.58–2.61 ( <i>m</i> )		1.83–1.90 ( <i>m</i> )	
4	2.68 ( <i>dd</i> , <i>J</i> =6.1, 13.5)	43.6	2.71–2.73 ( <i>m</i> )	43.4	2.43 ( <i>dd</i> , <i>J</i> =6.0, 10.6)	41.3		217.7	2.21 ( <i>dd</i> , <i>J</i> =6.6, 12.6)	44.2
5	6.68 ( <i>s</i> )	114.0	6.89 ( <i>s</i> )	120.6		118.9	6.40 ( <i>s</i> )	103.4	6.68 ( <i>s</i> )	109.8
6		151.3		146.8		149.6		152.5		155.6
7		120.7		124.5		121.6		114.9		123.8
8	7.02 ( <i>s</i> )	129.3	7.12 ( <i>s</i> )	129.3		129.0	6.83 ( <i>s</i> )	127.9	7.00 ( <i>s</i> )	129.4
9		135.4		140.4		136.6		124.0		135.0
10		139.0		138.7		138.7		153.2		138.5
11	1.29 ( <i>d</i> , <i>J</i> =7.2)	22.4	1.31 ( <i>d</i> , <i>J</i> =6.6)	21.2	1.27 ( <i>d</i> , <i>J</i> =6.6)	21.9	1.24 ( <i>d</i> , <i>J</i> =7.2)	19.1	1.27 ( <i>d</i> , <i>J</i> =7.2)	22.6
12	2.20–2.25 ( <i>m</i> )	31.7	2.22–2.25 ( <i>m</i> )	31.4	1.46–1.49 ( <i>m</i> )	31.4	2.62–2.65 ( <i>m</i> )	41.0	2.22–2.25 ( <i>m</i> )	32.2
13	0.75 ( <i>d</i> , <i>J</i> =6.6)	17.2	0.77 ( <i>d</i> , <i>J</i> =6.6)	17.0	0.48 ( <i>d</i> , <i>J</i> =7.2)	18.8	1.12 ( <i>t</i> , <i>J</i> =6.6)	18.3	0.75 ( <i>d</i> , <i>J</i> =6.6)	17.6
14	1.04 ( <i>d</i> , <i>J</i> =6.6)	21.2	1.04 ( <i>d</i> , <i>J</i> =6.6)	20.6	0.59 ( <i>d</i> , <i>J</i> =7.2)	21.2	1.12 ( <i>t</i> , <i>J</i> =6.6)	18.3	1.04 ( <i>d</i> , <i>J</i> =6.6)	21.5
15	2.26 ( <i>s</i> )	15.4	2.33 ( <i>s</i> )	15.6	2.28 ( <i>s</i> )	16.2	2.18 ( <i>s</i> )	15.1	2.21 ( <i>s</i> )	16.1
MeO									3.82 ( <i>s</i> )	55.2
AcO			2.18 ( <i>s</i> )	19.5, 169.2						

In the HMBC spectrum of **1**, the signals at δ(H) 7.02 (*s*, H–C(8)) showed correlations with δ(C) 32.2 (C(1)) and 15.4 (C(15)), and the signal at δ(H) 6.68 (*s*, H–C(5)) correlated with δ(C) 43.6 (C(4)) (Fig.). In the NOESY spectrum, correlations were observed between H–C(8) and both δ(H) 2.26 (*s*, Me(15)) and 2.73 (*m*, H–C(1)), as well as between H–C(5) and both δ(H) 2.68 (*m*, H–C(4)) and 2.22 (*m*, H–C(12)). These observations suggested that compound **1** was a calamenene-type sesquiterpenoid with a rearranged Me group at position 7.




Figure. Key HMBC and NOESY correlations for **1**

The fact that no NOE was observed between H–C(1) and H–C(4), and analysis of the coupling constants for H–C(1) ( $J(1,2\alpha)=4.8$ ,  $J(1,2\beta)=8.7$ ,  $J(1,11)=7.2$  Hz) and for H–C(4) ( $J(4,3\alpha)=7.2$ ,  $J(4,3\beta)=6.0$ ,  $J(4,12)=7.2$  Hz), as determined by homo-decoupled  $^1\text{H-NMR}$  experiments, indicated  $\beta$ -orientation of the Me(11) group and  $\alpha$ -orientation of the *i*-Pr group [9]. We tried to obtain suitable crystals for X-ray crystallography by transforming **1** into its acetate **1a** ( $M^+$  at  $m/z$  260.1742) or the corresponding methyl ether **4** ( $M^+$  at 232.1870). However, all crystallization attempts were unsuccessful. In the NOESY spectra of **1a** and **4**, the Ac and MeO H-atoms exhibited NOEs with H–C(5) and Me(15), which further confirmed the above conclusions. From the above results, the structure of **1** was, thus, established as (5*S*\*,8*R*\*)-5,6,7,8-tetrahydro-3,5-dimethyl-8-(1-methylethyl)naphthalen-2-ol, and the compound was named *chiloscyphenol A*.

Compound **2**, a yellowish, optically active oil ( $[\alpha]_{\text{D}}^{23} = +98.5$  ( $c=0.50$ , MeOH)), was determined to have the molecular formula  $\text{C}_{15}\text{H}_{22}\text{O}_2$  ( $m/z$  234.1605). The  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  data of **2** (Table 1) were similar to those of **1**, except for one more OH substituent at the benzene ring, as confirmed by only one aromatic  $^1\text{H-NMR}$  resonance at  $\delta(\text{H})$  7.06 (s). HMBC and NOESY experiments showed that compound **2** was also a rearranged calamenene-type sesquiterpenoid. Its structure was determined as (5*S*\*,8*R*\*)-5,6,7,8-tetrahydro-3,5-dimethyl-8-(1-methylethyl)naphthalen-1,2-diol, and it was named *chiloscyphenol B*.

Compound **3** had the molecular formula  $\text{C}_{15}\text{H}_{21}\text{O}_3$  ( $m/z$  249.1480). The  $^1\text{H-NMR}$  spectrum (Table 1) displayed the signals of two aromatic H-atoms, three Me groups at tertiary C-atoms, one Me group on an aromatic ring, and two  $\text{CH}_2$  moieties. From the DEPT spectrum of **3**, the 15 carbon signals could be assigned to four Me, two  $\text{CH}_2$ , two CH, and seven quaternary C-atoms, including one C=O signal at  $\delta(\text{C})$  217.7 (C(4)). The Me group on the aromatic ring was at C(7) according to a NOESY experiment. Thus, the structure of **3** was determined as 6-(2,4-dihydroxy-5-methylphenyl)-2-methylheptan-3-one, and the compound was named *chiloscyphone A*.

Compound **4**, a yellowish, optically active oil ( $[\alpha]_{\text{D}}^{22} = +98.5$  ( $c=0.50$ , MeOH)), was found to have the molecular formula  $\text{C}_{16}\text{H}_{24}\text{O}$  ( $m/z$  232.1870). The  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  spectroscopic data were identical to those of the synthesized methyl ether derivative obtained from **1**. Thus, the structure of **4** was identified as (1*S*\*,4*R*\*)-1,2,3,4-tetrahydro-1,7-dimethyl-4-(1-methylethyl)-6-methoxynaphthalene.

Note that compounds **1–4** are the first examples of sesquiterpenoids with a *rearranged* calamenene skeleton isolated from liverworts.

The ESI mass spectrum of compound **5** exhibited the molecular-ion peak at  $m/z$  270.4. In the HR-EI mass spectrum, the  $[M - H_2O_2]^+$  peak appeared at  $m/z$  236.1801 ( $C_{15}H_{24}O_2^+$ ; calc. 236.1776). So, the elemental composition of **5** was determined as  $C_{15}H_{26}O_4$ . An eudesmane skeleton was derived from MS, and 1D- and 2D-NMR data (Table 2). The olefinic signals at  $\delta(C)$  145.26 (C(4)) and 114.86 (C(14)) suggested  $\Delta^{4(14)}$  unsaturation, as confirmed by two vinylic signals in the  $^1H$ -NMR spectrum at  $\delta(H)$  5.28 (s) and 5.35 (s). A DEPT experiment showed two CH signals at  $\delta(C)$  86.66 and 71.50 as well as one quaternary carbon at  $\delta(C)$  74.94, indicating the presence of three oxygenated C-atoms. A 7-OH group was inferred from HMBC correlations between a pair of Me doublets at  $\delta(H)$  0.94 and 0.97 (Me(12) and Me(13)) with  $\delta(C)$  74.94 (C(7)). The signal at  $\delta(H)$  3.99, corresponding to  $\delta(C)$  71.50 according to the HMQC spectrum, showed HMBC correlations to both  $\delta(C)$  74.94 and 145.26 (C(4)). The signal at  $\delta(H)$  71.50, bearing another OH group, was assigned to C(6). So, the other two O-atoms required a hydroperoxide (OOH) function, which was placed at C(3), its  $\alpha$ -orientation being derived from the small coupling constant for H–C(3) at  $\delta(H)$  4.43 (t,  $J=3.0$  Hz). Furthermore, the  $\beta$ -configuration of the 6-OH group was deduced from a NOESY cross-peak between  $\delta(H)$  2.74 (d,  $J=1.8$  Hz, H–C(5)) and  $\delta(H)$  3.99 (s, H–C(6)). Finally, the 7-OH group at C(7) was assumed to be  $\alpha$ -oriented by analogy to known eudesmanes [10].

From the above data, compound **5** was identified as 3 $\alpha$ -hydroperoxyeudesm-4(14)-ene-6 $\beta$ ,7 $\alpha$ -diol (= (1*S*\*,2*R*\*,4*aR*\*,7*R*\*)-decahydro-7-hydroperoxy-4a-methyl-2-(1-methylethyl)-8-methylidenenaphthalene-1,2-diol).

Table 2.  $^1H$ - and  $^{13}C$ -NMR Data of **5** and **6**. At 600 ( $^1H$ ) and 150 MHz ( $^{13}C$ ), resp.;  $\delta$  in ppm,  $J$  in Hz. Arbitrary atom numbering.

Position	<b>5</b> <sup>a)</sup>		<b>6</b> <sup>b)</sup>	
	$^1H$	$^{13}C$	$^1H$	$^{13}C$
1	1.16–1.19 ( <i>m</i> ) 1.58–1.60 ( <i>m</i> )	38.00	1.48–1.51 ( <i>m</i> ) 1.04–1.06 ( <i>m</i> )	35.23
2	1.89–1.92 ( <i>m</i> )	25.91	1.71–1.74 ( <i>m</i> ) 1.57–1.61 ( <i>m</i> )	28.00
3	4.43 ( <i>t</i> , $J=3.0$ )	86.67	3.64 ( <i>br. s</i> )	68.39
4		145.26		131.49
5	2.74 ( <i>d</i> , $J=1.8$ )	42.76		138.25
6	3.99 ( <i>s</i> )	71.50	4.32 ( <i>d</i> , $J=3.0$ )	68.44
7		74.94		73.96
8	1.60–1.63 ( <i>m</i> ) 1.75–1.77 ( <i>m</i> )	26.94	1.60–1.65 ( <i>m</i> ) 1.38–1.42 ( <i>m</i> )	26.17
9	1.35–1.39 ( <i>m</i> ) 1.58–1.60 ( <i>m</i> )	35.61	1.52–1.57 ( <i>m</i> ) 1.18 ( <i>d</i> , $J=6.6$ )	36.33
10		34.70		33.21
11	2.00–2.02 ( <i>m</i> )	32.52	1.82–1.89 ( <i>m</i> )	32.70
12/13	0.94/0.97 ( <i>2d</i> , $J=6.6$ )	15.77/15.84	0.85/0.87 ( <i>2d</i> , $J=6.6$ )	16.44/16.28
14	5.28, 5.35 ( <i>2 br. s</i> )	114.86	1.70 ( <i>s</i> )	17.03
15	1.70 ( <i>s</i> )	19.26	1.07 ( <i>s</i> )	25.71

<sup>a)</sup> In  $CDCl_3$ . <sup>b)</sup> In  $(D_6)DMSO$ .

Compound **6** was obtained as a colorless oil with the molecular formula  $C_{15}H_{26}O_3$ , as deduced by ESI-MS ( $M^+$  at  $m/z$  254.7) and HR-EI-MS ( $[M - H_2O]^+$  at  $m/z$  236.1833). Four Me groups and a tetrasubstituted C=C bond were evident in the NMR spectra (Table 2), which also suggested an eudesmane skeleton. Furthermore, the carbon signals at  $\delta(C)$  68.39, 68.44, and 73.96 indicated two secondary and one tertiary O-bearing C-atoms. This was in good agreement with the  $^1H$ -NMR data of **6**, which exhibited two carbinol H-atoms at  $\delta(H)$  3.64 (br. s, H-C(3)) and 4.32 (*d*,  $J = 3.0$ , H-C(6)). These data clearly pointed to an eudesmane skeleton with  $\Delta^{4,5}$  unsaturation and OH groups in positions 3, 6, and 7. The relative  $\alpha$ -configuration of the 3-OH group was deduced by a NOESY correlation between  $\delta(H)$  3.64 and 1.49 ( $H_\beta$ -C(1)). The 6-OH and 7-OH functions were both assumed to be  $\alpha$ -configured due to NOEs between Me(15) ( $\delta(H)$  1.07 (*s*)) and both H-C(11) ( $\delta(H)$  1.86 (*m*)) and H-C(6).

From the above data, the structure of compound **6** was identified as eudesm-4-ene-3 $\alpha$ ,6 $\alpha$ ,7 $\alpha$ -triol (= (2*R*\*,4*aR*\*)-1,2,3,4,4*a*,5,6,7-octahydro-4*a*,8-dimethyl-2-(1-methylethyl)naphthalene-1,2,7-triol).

We kindly acknowledge Mrs. Gao Yanhui and Xing Jie for recording the high-resolution MS data. This research was supported by NSFC (No. 30271537).

### Experimental Part

TLC was carried out on silica-gel-precoated glass plates (*Kieselgel 60 F<sub>254</sub>*; Merck) eluting with petroleum ether (PE)/Me<sub>2</sub>CO 1:1, 2:1, and 3:1, or with CHCl<sub>3</sub>/MeOH 10:1. Silica gel 60 (70–230  $\mu$ m; Merck) was employed for normal-phase column chromatography (CC). Reverse-phase CC was performed on *Sephadex LH-20* with CHCl<sub>3</sub>/MeOH 1:1. Optical rotations were measured on a *Perkin-Elmer 341* polarimeter at 589 nm and 20°.  $^1H$ - and  $^{13}C$ -NMR Spectra were recorded at 600 and 150 MHz, resp., on a *Bruker AVANCE-600* spectrometer in CDCl<sub>3</sub> and (D<sub>6</sub>)DMSO; chemical shifts  $\delta$  in ppm rel. to residual solvent peaks ( $\delta(H)$  7.24,  $\delta(C)$  77.0 for CDCl<sub>3</sub>;  $\delta(H)$  2.50,  $\delta(C)$  39.8 for (D<sub>6</sub>)DMSO). HR EI-MS was performed on a *Waters GCT* system using He (60 kPa, 1 ml/min) as carrier gas. Samples were analyzed on a *HP-5* column (15 m  $\times$  0.25 mm; 0.25  $\mu$ m film). ESI-MS Data were recorded on an *API-4000* mass spectrometer; in  $m/z$ .

*Plant Material.* *Chiloscyphus polyanthus* was gathered at Mount Tai, Shandong, China, in August 2003. *Bazzania japonica* was collected at Shiwan Mountains, Guangxi, China, in May 2001. The plants were identified by Rui-Liang Zhu, and voucher specimens were deposited at the School of Pharmaceutical Sciences, Shandong University, China.

*Extraction and Isolation.* The EtOH extract of *C. polyanthus* (78 g) was separated into 18 fractions (Fr.) by CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH). Fr. 5, eluted with CHCl<sub>3</sub>/MeOH 85:1, was subjected to RP-CC (*Sephadex LH-20*, CHCl<sub>3</sub>/MeOH 1:1) to afford **1** (35.0 mg), **3** (15.2 mg), and **5** (7.5 mg). Fr. 11 and Fr. 16, eluted with CHCl<sub>3</sub>/MeOH 60:1, were rechromatographed (1. SiO<sub>2</sub>, CHCl<sub>3</sub>/MeOH; 2. *Sephadex LH-20*) to provided **2** (17.6 mg) and **6** (10.5 mg).

The Et<sub>2</sub>O extract (12 g) of *B. japonica* was subjected to CC (SiO<sub>2</sub>; PE/Me<sub>2</sub>CO gradient) to yield eleven fractions. Fr. 8, eluted with PE/Me<sub>2</sub>CO 30:1, was purified by RP-CC (*Sephadex LH-20*; CHCl<sub>3</sub>/MeOH 1:1), which yielded nine subfractions (Fr. 8.1–8.9). Fr. 8.4 (320 mg) was further separated by CC (SiO<sub>2</sub>; PE/Me<sub>2</sub>CO gradient) to afford **4** (15 mg).

*Derivatization of 1.* a) *Methylation.* To a soln. of **1** (8 mg) in CDCl<sub>3</sub> (2 ml), diazomethane (2 ml) was added, and the mixture was stirred at 20° for 5 h. The resulting soln. was concentrated *in vacuo* to afford **4** (4.2 mg). The anal. data of semi-synthetic **4** were identical with those of the purified, natural sample.

b) *Esterification.* To a soln. of **1** (10 mg) in CDCl<sub>3</sub> (3 ml) was added Ac<sub>2</sub>O (1 ml), and the mixture was stirred at 20° for 4 h. The org. phase was washed with H<sub>2</sub>O (3  $\times$ ) and then evaporated *in vacuo* to afford the acetate **1a** (5.6 mg) as a colorless oil. HR-EI-MS: 260.1742 ( $M^+$ , C<sub>17</sub>H<sub>24</sub>O<sub>2</sub><sup>+</sup>; calc. 260.1776).

## REFERENCES

- [1] Y. Asakawa, in 'Progress in the Chemistry of Organic Natural Products', Ed. W. Herz, G. W. Kirby, R. E. Moore, W. Steglich, C. Tamm, Springer-Verlag, Vienna, 1995, Vol. 65, p. 1.
- [2] Y. Asakawa, *Phytochemistry* **2001**, 56, 297.
- [3] G. Y. Li, B. Ma, H. X. Lou, *Nat. Prod. Res. Dev.* **2002**, 14, 5.
- [4] M. Toyota, T. Saito, Y. Asakawa, *Phytochemistry* **1999**, 51, 913.
- [5] Y. Asakawa, M. Toyota, A. Ueda, M. Tori, Y. Fukazawa, *Phytochemistry* **1991**, 30, 3037.
- [6] R. H. Lu, C. Paul, S. Basar, W. A. König, T. Hashimoto, Y. Asakawa, *Phytochemistry* **2003**, 63, 581.
- [7] Z. J. Li, H. X. Lou, W. T. Yu, P. H. Fan, D. M. Ren, B. Ma, M. Ji, *Helv. Chim. Acta* **2005**, 88, 2637.
- [8] W. Zhang, H. X. Lou, G. Y. Li, H. M. Wu, *J. Asian Nat. Prod. Res.* **2003**, 5, 189.
- [9] K. Nabeta, K. Katayama, S. Nakagawaraa, K. Katoh, *Phytochemistry* **1993**, 32, 117.
- [10] M. N. Todorova, E. T. Tsankova, *Phytochemistry* **1999**, 52, 1515.

Received July 5, 2006